Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Ther-Rx Corporation Stories

2013-08-05 12:27:55

Single dose prescription treatment for bacterial vaginosis now available for prescribing ST. LOUIS, Aug. 5, 2013 /PRNewswire/ -- Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHQ/KVPBQ) announced today that Clindesse® (clindamycin phosphate) Vaginal Cream, 2% indicated for the treatment of bacterial vaginosis (BV) in non-pregnant women, is now available for prescribing. Wholesalers have...

2013-01-24 08:31:28

ST. LOUIS, Jan. 24, 2013 /PRNewswire/ -- Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHA/KVPHB), and Perrigo Company (Nasdaq: PRGO; TASE) announced today that Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by Candida) in non-pregnant women(1), is now available for prescribing. Gynazole-1...

2011-11-08 15:31:00

ST. LOUIS, Nov. 8, 2011 /PRNewswire/ -- Recent testing conducted by independent laboratories, commissioned by Ther-Rx Corporation, a subsidiary of K-V Pharmaceutical Company (the "Company") (NYSE: KV.A/KV.B), shows that multiple samples of both compounded 17P drug formulations and active pharmaceutical ingredient (API) that may be used in compounded 17P failed to meet certain established standards for potency and purity. These findings, which have been submitted to the U.S. Food and...

2011-04-01 08:15:00

ST. LOUIS, April 1, 2011 /PRNewswire/ -- As part of its ongoing efforts to ensure that high-risk women have access to FDA-approved Makena instead of unapproved, unregulated compounded drugs, Ther-Rx Corporation, a subsidiary of K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), announced today important initiatives to reduce the cost of Makena(TM) (hydroxyprogesterone caproate injection) and encourage stakeholders to provide timely access to this important FDA-approved medication....

2011-03-30 14:20:00

ST. LOUIS, March 30, 2011 /PRNewswire/ -- Ther-Rx Corporation takes very seriously the public concerns raised regarding the list price of Makena. We are committed to ensuring that this significant, FDA-approved medication is covered at an affordable cost and accessible to all women who are prescribed Makena. We are finalizing solutions to the concerns, and will announce them by the end of the week. We share the Food and Drug Administration's (FDA) long-standing position to ensure that...

2011-03-08 10:48:00

ST. LOUIS, March 8, 2011 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a specialty pharmaceutical company, along with its branded subsidiary, Ther-Rx Corporation, today announced the details of its patient assistance program for Makena(TM) -eligible patients. Makena will be available for prescribing the week of March 14. "Prior to FDA approval of Makena, women who could benefit from therapy may have faced barriers to access due to the absence of a...

2011-02-04 07:30:00

ST. LOUIS, Feb. 4, 2011 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a specialty pharmaceutical company, announced today that it has been informed by Hologic, Inc. that the U.S. Food and Drug Administration (FDA) granted approval for Makena(TM) (hydroxyprogesterone caproate injection). Makena, commonly referred to as "17P," is the first and only FDA-approved treatment indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have...

2010-06-30 05:00:00

ST. LOUIS, June 30 /PRNewswire/ -- A new survey shows a majority of new and expectant moms have not discussed preterm birth with their healthcare providers, despite the fact that early prenatal care, including discussion about lifestyle habits and medical history, may give babies a better chance of a healthy, full-term birth. This new survey, titled SPEAKing (Survey on Perceptions, Experiences, Assessment and Knowledge) About Preterm Birth, was conducted among moms and healthcare...

2009-02-03 18:29:00

ST. LOUIS, Feb. 3 /PRNewswire/ -- Ther-Rx Corporation, a subsidiary of KV Pharmaceutical Company (NYSE: KVa/KVb), is issuing a voluntary nationwide recall of prescription prenatal and iron supplement nutritionals as identified below (all lots within their expiration dates) at a wholesale level. The Company is taking this action as a precautionary measure, because the products may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing...

2009-01-28 12:01:00

ST. LOUIS, Jan. 28 /PRNewswire-FirstCall/ -- Ther-Rx Corporation, a subsidiary of KV Pharmaceutical (NYSE: KVa/KVb), is issuing, as previously disclosed by KV Pharmaceutical Company on January 26, 2009, a voluntary nationwide recall of the products identified below (all lots within expiration) as a precautionary measure because they may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practices (cGMPs). One of the products,...